Publication: 4855

Publication: 4855

A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (A-DREAM / Alliance A032101)

Google Scholar

Citation:

Meeting Instance:: ASCO 2026
Year:: 2026
Type:: Abstract
Sub type:
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 4951

Program:: OGC
Primary Committee:: GU
Sec. Committees:

Pharmas:
Grants:: U10CA180821, U10CA180882, UG1CA189823

Corr. Author:
Authors:: Atish D. Choudhury Karla Ballman Melissa A. Reimers Andrew Laccetti Fabrice Smieliauskas Praful Ravi Han Xiao Katharine Dooley David Hillman Gina L. Mazza Benjamin Gartrell Preston Steen Thomas J. Smith Himisha Beltran Ronald C. Chen Stephanie Berg Rana R. McKay Matthew D. Galsky Jonathan E. Rosenberg Michael Morris

Networks:: CA249, KANSAS, LAPS-MA036, LAPS-MD017, LAPS-MO011, LAPS-NY016, MI020, MONTEFIORE, NY021, NY093, SANFORD

Study: Alliance-A032101
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: